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Abstract
Background: To assess prognostic and predictive effects of clinical and biochemical factors in our published
randomized study of a weekly low dose (metronomic arm) versus a conventional dosage of zoledronic acid
(conventional arm) in breast cancer patients with bone metastases.
Methods: Treatment outcome of 60 patients with bone metastases were used to assess impacts of following
potential prognostic factors, estrogen receptor status, lymph node status, 2 year-disease free interval (DFI), numbers
of chemotherapy regimens administered, interventions, and serum levels of VEGF, N-telopeptide of type I collagen
(NTx), CEA, and CA 15-3.
Results: In univariate analyses, patients pretreated with 2 or fewer chemotherapy regimens, ER-positive tumors, 3
or fewer lymph nodes, DFI of more than 2 years, serum VEGF of less than 500 pg/mL after 3 months of
intervention, serum CEA and CA 15-3 of less than ULN, and baseline serum NTx of less than 18 nM BCE had
significantly longer progression free survival (PFS). The multivariate analysis showed that ER positivity (hazard ratio
[HR], 0.295; 95% confidence interval [CI], 0.141-0.618; P = 0.001), serum VEGF of less than 500 pg/mL after 3 months
of intervention (HR, 2.220; 95% CI, 1.136-4.338; P = 0.020), baseline serum NTx of less than 18 nM BCE (HR, 2.842;
95% CI, 1.458-5.539; P = 0.001), and 2 or fewer chemotherapy regimens received (HR, 7.803; 95% CI, 2.884-21.112; P
= 0.000) were associated with a better PFS. When evaluating the predictive effect of the biochemical factors, an
interaction between NTx and zoledronic acid intervention was shown (P = 0.005). The HR of weekly low dose
versus a conventional dosage of zoledronic acid was estimated to be 2.309 (99% CI, 1.067-5.012) in patients with
baseline serum NTx of more than 18 nM BCE, indicating a superiority of weekly low dose of zoledronic acid.
Conclusions: ER, serum VEGF level after intervention, and numbers of chemotherapy regimens administered are
prognostic but not predictive factors in breast cancer patients with bone metastases. Patients with baseline serum
NTx of more than 18 nM BCE might benefit more from weekly low-dose of zoledronic acid.
Trial registration: ClinicalTrials.gov unique identifier: ClinicalTrials.gov: NCT00524849
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Breast cancer is the most frequent malignancy in
women. Bone metastases play a crucial role in this can-
cer entity and are an important cause of disability and
morbidity. 70% of women with advanced disease suffer
from bone metastases [1]. The median survival of bone
metastases is about 2 years, and survival may be pro-
longed with new treatment regimens [2]. Zoledronic
acid (Zometa, Novartis) is the only and the most potent
bisphosphonate indicated for the management of solid
tumor with bone metastases [3,4]. While the use of zole-
dronic acid once every year is sufficient for the treat-
ment of postmenopausal osteoporosis, dosing every 3-4
weeks has emerged as an appropriate established strat-
egy for the prevention and management of bone metas-
tases [5,6]. However, for maximizing its antitumor
effects, the dosing schedule of zoledronic acid must be
optimized [7]. Despite the completion of a randomized
weekly low dose of zoledronic acid therapy study in
breast cancer patients with bone metastases, no clear
recommendation concerning its use outside of clinical
studies can be given. Although metronomic low-dose
zoledronic acid is more effective than the conventional
regimen and generates sustained reductions in circulat-
ing VEGF and NTx levels, as well as stabilization of
serum CA 15-3 levels, no significant benefit in survival
after a relative short follow-up could be shown [8].
Several biomarkers detected by biochemical analysis,
such as NTx, CEA, CA15-3, or VEGF, are found to be
of prognostic value in breast cancer patients with bone
metastases treated with zoledronic acid [7-12]. The
prognostic value of VEGF, an endothelial-cell-specific
mitogen and survival factor, has been studied exten-
sively by immunohistochemical assay or enzyme-linked
i m m u n o s o r b e n ta s s a y( E L I S A )i nv a r i o u ss o l i dt u m o r s .
VEGF’s status is an independent indicator of prognosis
in most types of solid tumors. Over-expression of
VEGF results in early relapse and poor survival. In
addition, VEGF levels correlate with prognosis of
breast cancer patients and intervention-induced reduc-
tions indicate a good prognosis [9,10]. NTx, a bone
resorption marker correlates with both the presence
and extent of bone metastases [11,12]. Elevated serum
levels of NTx in the majority of patients with bone
metastases can be normalized within 3 months of
treatment of zoledronic acid [11]. Patients with a nor-
malized NTx after treatment with zoledronic acid have
a similar prognosis as those with a normal pretreat-
ment NTx level, but a longer progression-free survival
than those still with higher NTx levels after treatment
[11,12]. Therefore, serum NTx level can be used to
assess not only the inhibition of osteoclastic activity by
bisphosphonates, but also the parameters of disease
outcome. CEA and CA 15-3 are the most commonly
used tumor markers. Use of CEA in conjunction with
CA 15-3 improves the detection of systemic disease,
while CA 15-3 itself is quite useful in metastatic bone
breast cancer [13,14].
In the current study, we analyzed the prognostic and
predictive value of these clinical and biochemical factors
in 60 breast cancer patients with bone metastases who
were treated within a randomized study (ClinicalTrials.
gov number, NCT00524849) comparing weekly low-
dose of zoledronic acid with conventional dose of zole-
dronic acid [8]. This is the first randomized study
between weekly low-dose of zoledronic acid and con-
ventional dose of zoledronic acid investigating the prog-
nostic and predictive effect of clinical and biochemical
markers.
Methods
Study design
Eligibility Criteria
Eligibility criteria included stage IV breast cancer with
bone metastases. All patients had to be female; 18 years
o fa g eo ro l d e r ;w i t hap e r f o r m a n c es t a t u so f0 ,1 ,o r2
on the Eastern Cooperative Oncology Group (ECOG)
scale; a life expectancy of more than 3 months; and ade-
quate organ function, including Cr ≤ 265 μmol/L, CrCl
≥ 30 mL/min, and Ca
2+ levels ranging from 2.0 mmol/L
to 3.0 mmol/L. A negative pregnancy test was necessary
for women in childbearing age. Diagnosis of bone
metastases had to be made using X-ray, CT scan, or
MRI. No anti-tumor therapy for stage IV breast cancer
was permitted within 28 days before administration of
the trial agent.
Exclusion Criteria
Patients were excluded from the study participation for
any of the following reasons: (1) concomitant liver,
brain, or symptomatic lung metastases (defined as
hemoptysis, severe cough, and shortness of breath); (2)
history of other malignancy, (unless more than 5 years
disease-free) and excluding completely resected non-
melanoma skin cancer; (3) active or uncontrolled infec-
tion; (4) concurrently active dental problems including
infection of the teeth (maxillary or mandibular), dental
trauma, or a concurrent or prior diagnosis of osteone-
crosis of the jaw; (5) recent (within 6 weeks) or planned
dental or jaw surgery; (6) history of uncontrolled or
symptomatic angina, arrhythmias, or congestive heart
failure; (7) previous treatment with any bisphosphonates
within 1 month before study initiation; (8) known
hypersensitivity to bisphosphonates; (9) history of treat-
ment with calcitonin, gallium nitrate, or mithramycin
within 14 days before study; or (10) pregnancy or lacta-
tion in potentially eligible women.
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advanced breast cancer patients with bone metastases to
investigate the effects of two dose schedule of zoledronic
acid. In the weekly low-dose arm, zoledronic acid (1 mg)
was administered intravenously (IV) on days 1, 8, 15,
and 22, followed by zoledronic acid (4 mg IV) on a stan-
dard 28-day schedule. In the conventional arm, zoledro-
nic acid (4 mg IV) was administered every 4 weeks. The
study was reviewed by the ethics committee of Fudan
University Shanghai Cancer Center, and a written
informed consent was obtained from all patients. The
details of the study are described elsewhere [8].
Blood samples
Blood samples of 60 patients treated within a rando-
mized study comparing weekly low-dose of zoledronic
acid with conventional dose of zoledronic acid between
November 2006 and August 2008 were detected for the
biochemical factors VEGF, NTx, CEA, and CA 15-3 to
evaluate their prognostic and predictive effects. All the
samples (4 samples per patient) were sent to Clinical
Laboratory, Fudan University Shanghai Cancer Center,
and stored for further biochemical analysis. No selection
of the material was done and 228 specimens (228/240,
95%) were evaluable for analysis. For the remaining 12
time points (5 for weekly low-dose arm, 7 for conven-
tional arm), no samples were available.
Peripheral venous blood samples (12 mL) were col-
lected immediately (within 15 minutes) prior to zoledro-
nic acid infusion on days 1, 15, 29, and 90. After
collection, the samples were kept at room temperature
(approximately 25°C) for 30 minutes to allow clotting,
and were immediately (within 5 minutes) centrifuged at
1,000 × g for 15 minutes. Serum samples were aliquoted
and stored at -80°C until assessment. White blood cell
and platelet counts, hemoglobin, hepatic and renal func-
tion, serum electrolytes, and CEA and CA 15-3 levels
were assessed at the time points mentioned above.
Biochemical markers
Serum levels of VEGF were assayed using a solid-phase
sandwich enzyme-linked immunosorbent assay (ELISA;
Quantikine Immunoassays R&D Systems, France). The
assay was performed in a single-blinded manner accord-
ing to the manufacturer’s instructions. Each sample was
analyzed in duplicate. The minimum detectable level of
VEGF was typically less than 9.0 pg/mL. The VEGF cut-
off value was 500.0 pg/mL [15]. Corresponding platelet
counts were also determined.
Serum levels of Osteomark NTx were assayed using a
competitive-inhibition ELISA kit (Ostex International
Inc., USA). NTx in the patient sample competed with
the NTx epitope in the microplate well for antibody
binding sites. The amount of bound labeled antibody
was measured by colorimetric generation of a peroxide
substrate at 450 nm. Assay values were reported as
nanomoles Bone Collagen Equivalents per liter (nM
BCE). The NTx cut-off value was 18 nM BCE [16].
Serum levels of CEA were assayed using electrochemi-
luminescence immunoassay -sandwich technique by
cobas e immunoassay analyzers (Beckman Couter Inc.,
USA). Assay values were reported as micro gram per
liter (μg/L). The range of normal value of CEA is 0-10
μg/L.
Serum levels of CA 15-3 were assayed using ELISA-
sandwich technique by Access immunoassay system
(Roche Diagnostics, USA). Assay values were reported
as unit per milliliter (U/mL). The range of normal value
of CA 15-3 is 0-25 U/mL.
Statistical analysis
All statistical analyses were carried out on an intention-
to-treat basis using the SPSS 15.0 software package
(Chicago, IL, USA). The end point for all analyses was
progression-free survival time (PFS). Progression-free
survival time was defined as time from the date of ran-
domization to the date of disease progression, or death
from any cause. For patients who did not experience the
event of interest during following up, the time from the
date of randomization to the last documented follow-up
was used as censored observation. The progression-free
survival rates were calculated according to the Kaplan-
Meier method. The hazard ratio between different
groups defined by treatment or prognostic factors with
corresponding confidence intervals was determined by
the Cox regression model.
All data analyses were carried out according to a pre-
specified analysis plan. The categorization of the prog-
nostic factors–number of positive lymph nodes, tumor
size, tumor grade, Her-2 status, estrogen receptor status,
2-year DFI (from surgery to first recurrence) - was pre-
defined as used in the primary analysis and report of
this study [8]. All biochemical analyses are based on all
60 patients and 228 samples. In a first step, the effects
of the clinical and biochemical factors were analyzed in
this patient population in a univariate analysis. Age,
number of positive lymph nodes, estrogen receptor sta-
tus, tumor size, tumor grade, Her-2 status, 2-year DFI
(from surgery to first recurrence), numbers of che-
motherapy regimens administered, interventions, base-
line serum levels of VEGF, NTx, CEA, and CA 15-3,
and VEGF levels at days 90 after intervention were
included in a Cox regression model.. In a second step, a
multivariate analysis of those clinical and biochemical
factors was done, which had shown a significant effect
in the univariate analyses at the 10% level.
For investigating the predictive effect of the clinical
and biochemical factors, interactions between zoledronic
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number of positive lymph nodes, 2-year DFI, numbers
of chemotherapy regimens administered, baseline serum
l e v e l so fV E G F ,N T x ,C E A ,a n dC A1 5 - 3 ,a n dV E G F
levels at days 90 after intervention were examined. After
completing the univariate analyses, a multivariate analy-
sis was done. Only variables with a significance of P <
0.05 in the univariate analyses were kept in the next
Cox regression model. Multivariate analysis was done
using a separate Cox regression model for each of these
factors. The interaction was tested by a conditional LR
test of equality of the treatment effects in the resulting
groups. In virtue of multiple testing, a significance level
of 1% was used for these tests. Additionally, the corre-
sponding multiplicative interactive effects were esti-
mated with 99% confidence intervals.
Results
Patient characteristics
For 60 patients, a complete data set of all investigated
clinical and biochemical factor was evaluable. The clini-
cal characteristics of the patients included in the current
study are listed in Table 1. The 2 groups were well
balanced with respect to their clinical and pathologic
features. All patients received chemotherapy or hormo-
nal therapy a minimum of 28 days after the first infu-
sion of zoledronic acid, with no significant differences
observed between the 2 arms in the use of anti-tumor
agents. The details are described elsewhere [8].
Table 2 shows the distribution of patients to the dif-
ferent categories of the biochemical factors.
Table 1 Patient characteristics
Metronomic arm Conventional arm P
No % No %
Median age (range) 46 (35-73) 51 (33-73) 0.1040
ER status + 22 73.3 18 60.0 0.3950
- 7 23.3 11 36.6
Her-2 status + 3 10.0 4 13.3 1.0000
- 22 73.3 24 80.0
Primary tumor T1, T2 26 86.7 30 100.0 0.1120
T3, T4 4 13.3 0 0
Disease free interval* >2 years 23 76.7 20 66.7 0.5670
≤ 2 years 7 23.3 10 33.3
Lymph node 0 ≤ N ≤ 3 25 83.3 22 73.3 0.5320
N>3 5 16.7 8 26.7
Previous radiotherapy yes 18 60.0 20 66.7 0.7890
no 12 40.0 10 33.3
Primary histology IDC 29 96.7 28 93.3 1.0000
ILC 1 3.3 2 6.7
Grade 1 9 30.0 6 20.0 0.7180
2 14 46.7 16 53.3
3 4 13.3 3 10.0
Menopausal pre 17 56.7 14 46.7 0.6060
post 13 43.3 16 53.3
Previous chemotherapy regimen ≤ 2 26 86.7 22 73.3 0.3330
>2 4 13.3 8 26.7
Bone metastasis sites 1 11 36.7 9 30.0 0.7850
≥ 2 19 63.3 21 70.0
* Disease free interval = date from surgery to first recurrence
Table 2 Biochemical factors investigated and
categorizing
Biochemical factor category No. %
Baseline NTx normal ≤ 18 nM BCE 30 50
abnormal > 18 nM BCE 30 50
Baseline VEGF normal ≤ 500 pg/ml 30 50
abnormal > 500 pg/ml 30 50
Baseline CEA normal ≤ 10 μg/L 42 70
abnormal > 10 μg/L 18 30
Baseline CA 15-3 normal ≤ 51 U/mL 21 35
abnormal > 51 U/mL 39 65
NTx (days 90) normal ≤ 18 nM BCE 34 56.7
abnormal > 18 nM BCE 16 43.3
VEGF (days 90) normal ≤ 500 pg/ml 29 48.3
abnormal > 500 pg/ml 21 42.7
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factors
As the data updated [8], the median follow-up time was
31.4 months (ranges, 19.0-42.3 months). In univariate
analyses of the clinical and biochemical factors, numbers
of pretreated chemotherapy regimens, ER status, num-
bers of lymph nodes, 2-year DFI, serum VEGF level
after 3 months of intervention, baseline serum CEA, CA
15-3, and NTx level showed a significant influence on
the progression-free survival. (Figure 1)
Multivariate analysis of prognostic clinical and
biochemical factors
T h er e s u l t so fam u l t i v a r i a t ea n a l y s i so ft h o s ec l i n i c a l
and biochemical factors at the 5% significance level in
univariate analyses are displayed in Table 3. ER positiv-
ity, serum VEGF of less than 500 pg/mL after 3 months
of intervention, baseline serum NTx of less than 18 nM
BCE, and 2 or fewer chemotherapy regimens were asso-
ciated with a significantly better PFS.
Analysis of predictive factors
Table 4 shows the results of the analyses regarding the
predictive effect of the different clinical and biochemical
factors (i.e., it was analyzed whether the treatment effect
of weekly low-dose zoledronic acid versus conventional-
dose zoledronic acid on progression free survival is het-
erogeneous in prognostic subgroups of patients defined
by these factors). The results of univariate and multi-
variate analyses for patients undergoing Metronomic
treatment are displayed in Table 5. Additionally, the
progression-free survival in different subgroups is shown
in Figure 2. In the univariate analyses, the weekly low-
d o s ez o l e d r o n i ca c i ds e e m st oh a v eam o r ep r o n o u n c e d
effect in the subgroup with ER negativity, DFI less than
2 years, number of previous chemotherapy no less than
Figure 1 Kaplan-Meier curves for progression-free survival with different biochemical and clinical factors. A. Kaplan-Meier curves for
progression-free survival. Notes: Patients with numbers of positive lymph nodes no more than 3 (N = 47), median = 6.3 months (95% CI, 4.1-8.6
months); patients with numbers of positive lymph nodes more than 3 (N = 13), median = 2.7 months (95% CI, 1.2-4.2 months); P = 0.012. B.
Kaplan-Meier curves for progression-free survival. Notes: Patients with DFI no less than 2 years (N = 43), median = 6.4 months (95% CI, 2.9-10.0
months); patients with DFI less than 2 years (N = 13), median = 5.1 months (95% CI, 3.6-6.7 months); P = 0.018. C. Kaplan-Meier curves for
progression-free survival. Notes: Patients with ER positive (N = 40), median = 7.0 months (95% CI, 5.3-8.8 months); patients with ER negative (N =
18), median = 2.8 months (95% CI, 2.2-3.4 months); P = 0.010. D. Kaplan-Meier curves for progression-free survival. Notes: Patients treated with 2
or less than 2 regimens (N = 48), median = 6.4 months (95%CI, 4.5-8.3 months); patients treated with more than 2 regimens (N = 12), median =
1.6 months (95%CI, 0.1-3.1 months); P = 0.024. E. Kaplan-Meier curves for progression-free survival. Notes: Patients with serum CEA baseline levels
of less than 10 μg/L (N = 42), median = 6.4 months (95% CI, 4.6-8.3 months); patients with serum CEA baseline levels of greater than 10 μg/L (N
= 18), median = 3.0 months (95% CI, 0-6.8 months); P = 0.019. F. Kaplan-Meier curves for progression-free survival. Notes: Patients with serum CA
15-3 baseline levels of less than 25 U/mL (N = 21), median = 10.6 months (95% CI, 3.5-17.8 months); patients with serum CA 15-3 baseline levels
of greater than 25 U/mL (N = 38), median = 4.2 months (95% CI, 1.0-7.3 months); P = 0.008. G. Kaplan-Meier curves for progression-free survival.
Notes: Patients with serum VEGF levels after 3 months of intervention of less than 500 pg/mL (N = 29), median = 10.0 months (95% CI, 4.3-15.7
months); patients with serum VEGF levels of 500 pg/mL or greater after 3 months of intervention (N = 21), median = 4.0 months (95% CI, 2.0-6.1
months); P = 0.014. H. Kaplan-Meier curves for progression-free survival. Notes: Patients with serum NTx baseline levels less than 18 nM BCE (N =
28), median = 8.1 months (95% CI, 4.2-11.9 months), patients with serum NTx baseline levels greater than 18 nM BCE (N = 32), median = 4.2
months (95% CI, 1.0-7.2 months); P = 0.003.
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with baseline serum NTx of greater than 18 nM BCE
After multivariate analyses, baseline NTx level is the
only factor for which a significant interactive effect with
treatment on progression-free survival can be shown.
The hazard ratio of weekly low-dose zoledronic acid
versus conventional-dose zoledronic acid is estimated as
2.309 (99% confidence interval, 1.067-5.012) in high
level of baseline NTx patients (> = 18.0 nM BCE), P =
0.005.
Discussion
Several pilot studies have shown an advantage for
weekly low-dose zoledronic acid in inducing an early
significant and long-lasting decrease of VEGF levels in
cancer patients [7,17]. Recently, after completion of a
randomized study comparing weekly low-dose zoledro-
nic acid with conventional-dose zoledronic acid in
breast cancer patients with bone metastases, it has
shown an advantage for weekly low-dose zoledronic
acid. Low-dose zoledronic acid is shown to be more
effective than the conventional regimen and generates
sustained reductions in circulating VEGF and NTx
levels, as well as stabilization of serum CA 15-3 levels
[8]. The analysis presented in this article was underta-
ken to evaluate clinical or biochemical factors, which
might predict the outcome after weekly low-dose or
conventional-dose zoledronic acid in these breast cancer
patients with bone metastases with poor prognostic fac-
tors; therefore, improve an individualization of the
patient management.
In the first step of our analysis, we investigated the
prognostic effect of the clinical and biochemical factors
on progression-free survival in a patient population,
which was treated in a randomized study protocol [8].
In a univariate analysis, after adjustment for treatment,
clinical factors such as pretreated chemotherapy regi-
mens, ER status, lymph nodes status, 2-year DFI, and
biochemical factors such as serum VEGF level after 3
months of intervention, baseline CEA, CA 15-3, and
Table 4 Subgroup analysis of PFS of patients treated with metronomic vs. conventional zoledronic acid
Clinical and biochemical factor HR (95% CI) P
DFI (year) > 2 1.318 (0.660-2.630) 0.437
≤ 2 3.455 (1.043-11.445) 0.043
ER status + 1.036 (0.504-2.130) 0.922
- 4.178 (1.130-15.450) 0.032
Lymph node status ≤ 3 1.340 (0.699-2.568) 0.378
>3 2.093 (0.636-6.893) 0.224
Numbers of previous chemotherapy ≤ 2 1.107 (0.586-2.093) 0.754
>2 11.440 (1.348-97.069) 0.025
Baseline CEA (ug/L) ≤ 10 1.281 (0.644-2.549) 0.481
>1 0 3.927 (1.179-13.079) 0.026
Baseline CA 15-3 (U/mL) ≤ 25 0.762 (0.258-2.251) 0.623
>2 5 2.087 (1.056-4.122) 0.034
Baseline NTx (nM BCE) ≤ 18 0.945 (0.399-2.241) 0.898
>1 8 2.520 (1.141-5.566) 0.022
Baseline VEGF (pg/mL) ≤ 500 2.337 (0.522-10.468) 0.267
> 500 1.186 (0.546-2.573) 0.667
VEGF (3 months after intervention) (pg/mL) ≤ 500 0.834 (0.340-2.046) 0.692
> 500 1.596 (0.619-4.115) 0.333
Table 3 Multivariate analysis of clinical and biochemical factors
Clinical and biochemical factor category HR (95% CI) P
Previous chemotherapy regimen ≤ 2 1 0.000
> 2 7.803 (2.884-21.112)
ER status - 1 0.001
+ 0.295 (0.141-0.618)
Baseline NTx ≤ 18 nM BCE 1 0.001
> 18 nM BCE 2.842 (1.458-5.539)
VEGF (days 90) ≤ 500 pg/ml 1 0.020
> 500 pg/ml 2.220 (1.136-4.338)
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metronomic zoledronic acid
Clinical and biochemical factor Patient population Multivariate
Variables in model Backward selection
HR (99% CI) P HR (99% CI) P
DFI (year) > 2 vs ≤ 2 1.811 (0.788-4.161) 0.026 –
ER status + vs - 0.753 (0.281-2.014) 0.459 –
Numbers of previous chemotherapy ≤ 2v s>2 0.414 (0.130-1.136) 0.050 –
Baseline CEA (ug/L) ≤ 10 vs > 10 1.633 (0.629-4.241) 0.186 –
Baseline CA 15-3 (U/mL) ≤ 25 vs > 25 1.283 (0.433-3.800) 0.554 –
Baseline NTx (nM BCE) ≤ 18 vs > 18 1.645 (0.652-4.150) 0.166 2.309 (1.067-5.012) 0.005
Figure 2 Kaplan-Meier curves for progression-free survival with different treatments. A. Kaplan-Meier curves for progression-free survival.
Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in
patients with DFI less than 2 years (N = 17), metronomic arm (N = 7), median = 7.0 months (95% CI, 4.7-9.3 months); conventional arm (N = 10),
median = 4.2 months (95% CI, 1.7-6.6 months); P = 0.033. B. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly
low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with ER negative (N = 18),
metronomic arm (N = 7), median = 7.0 months (95% CI, 0-17.3 months); conventional arm (N = 11), median = 2.7 months (95% CI, 0.9-4.6
months); P = 0.021. C. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic
arm) versus conventional dose zoledronic acid (conventional arm)] in patients with more than two of pretreated chemotherapy regimens (N =
12), metronomic arm (N = 4), median = 9.8 months (95% CI, 0-22.0 months); conventional arm (N = 8), median = 1.0 months (95% CI, 0.6-1.3
months); P = 0.007. D. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic
arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum CEA baseline levels of greater than 10 μg/L (N = 18),
metronomic arm (N = 9), median = 8.1 months (95% CI, 0-22.0 months); conventional arm (N = 9), median = 1.1 months (95% CI, 1.0-1.2
months); P = 0.017. E. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic
arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum CA 15-3 baseline levels of greater than 25 U/mL (N =
38), metronomic arm (N = 17), median = 7.0 months (95% CI, 5.8-8.2 months); conventional arm (N = 21), median = 1.9 months (95% CI, 1.2-2.7
months); P = 0.017. F. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic
arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum NTx baseline levels less than 18 nM BCE (N = 30),
metronomic arm (N = 14), median = 5.4 months (95% CI, 3.8-7.0 months); conventional arm (N = 16), median = 1.9 months (95% CI, 0-5.3
months); P = 0.018.
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gression-free survival. Patients with poor prognostic fac-
tors such as heavily treated with chemotherapy, ER
negativity, more than 3 lymph nodes, DFI less than 2
years, high levels of CEA, and CA 15-3 had a signifi-
cantly higher probability of relapse/death during follow-
up, which is consistent with other reports [13,14,18-22].
For bone metastases and potential antiangiogenic effect
of zoledronic acid, we added NTx and VEGF into analy-
sis. We first claimed that patients with low level of base-
line NTx and VEGF after intervention had a better
prognosis than patients with high level of baseline NTx
and VEGF after intervention tumors. No influence on
progression free survival could be shown for other fac-
tors including age, tumor size, tumor grade, menopause,
bone metastasis sites, baseline VEGF and NTx, CEA,
and CA 15-3 levels after intervention.
In the multivariate analysis of the clinical and bio-
chemical factors, numbers of pretreated chemotherapy
regimens, ER status, baseline NTx, and serum VEGF
level after 3 months of intervention were independent
prognostic factors for progression free survival, showing
that these factors were associated with a significant
downward progression free survival. The results for
numbers of pretreated chemotherapy regimens and ER
status are in line with data of several other studies
reporting a prognostic effect of these factors for breast
cancer patients [18,20]. The result for the prognostic
effect of NTx seems to be consistent with some studies
in the literature. Several clinical studies suggest that the
bone resorption marker, NTx, is associated with the pre-
sence and extent of metastases, response to treatment,
and prognosis [23-25]. Arguably, the serum VEGF levels
at 3-month time point, not the baseline serum VEGF
levels was shown as the independent prognostic factor
for PFS both in the univariate and multivariate analyses.
Four published studies, which evaluated the prognostic
value of serum VEGF level, revealed that high levels of
circulating VEGF levels is associated with poor survival
[15]. The explanation for prognostic value of serum
VEGF level at 3-month time point could be that the
VEGF values at that time reflect the dynamics of tumor
biology interacting with zoledronic acid. However, this
effect may need to be sustained with higher frequency
and a longer duration of zoledronic acid administration.
The second aim of our study was to investigate
whether the clinical or biochemical factors have predic-
tive effects (i.e., if treatment effects of weekly low-dose
zoledronic acid compared with conventional schedule
are different in subgroups defined by the clinical or bio-
chemical factors). This is the first study to investigate
the predictive factors of breast cancer patients with
bone metastases receiving weekly low-dose zoledronic
acid. Several former studies have shown some predictive
factors of conventional zoledronic acid or bisphospho-
nates naïve in bone metastases of several kinds of can-
cers. Lein et al. investigated in a study in 117 prostate
cancer patients with bone metastases receiving zoledro-
nic acid the predictive effect of a range of bone turnover
markers, they created cox regression models with clini-
cal factors and bone markers and eventually showed the
baseline NTx level as predictor of SREs (HR, 3.33; 95%
CI, 1.66-6.72, P = 0.0007) [26]. Coleman et al. investi-
gated in three large, randomized trials of 1824 patients
with bone metastases receiving bisphosphonates the
prognostic effects of NTx, and bone alkaline phospha-
tase (BAP) and found that high NTx level in each solid
tumor category were associated with a 4- to 6-fold
increased risk of death compared with low NTx levels
and BAP showed correlation with negative outcomes
[11]. Brown et al. investigated two phase III randomized
trials in 431 bisphosphonate-naïve patients with bone
metastases secondary to prostate cancer, non-small-cell
lung cancer, and other solid tumors from the predictive
and prognostic effect of a range of factors. They found
the predictive relationships for NTx and BAP levels for
the NSCLC, prostate cancer, and other tumors. Their
analysis showed that a high BAP level at baseline was
associated with an increased risk of negative clinical out-
comes compared to patients with low baseline BAP
levels (RR, 1.49; 95% CI, 1.02 to 2.17, P = 0.041).
Furthermore, it also revealed a statistically significant
association between baseline NTx levels, time to a first
skeletal related event (P = 0.026), risk of disease pro-
gression (P = 0.029) and death (P = 0.001) [12].
The major finding of our study was a predictive value
of NTx on treatment strategies. Patients with high level
of baseline NTx showed a higher progression-free survi-
val with weekly low-dose zoledronic acid compared with
conventional q-4 weeks regimen. Our results obtained
for the patients with weekly low-dose zoledronic acid
are different from other reports. First, several previous
studies have evaluated some predictive or prognostic
value of NTx level, but the treatment they used were
old generation of bisphosphonates such as pamidronate
and clodronate, which is not potent as zoledronic acid
in anti-bone resorption and potential antitumor effects
[23,25]. Several study use zoledronic acid, but NTx
prognostic or predictive value was obtained from
bisphosphonates naïve patients or patients receiving the
conventional dose of zoledronic acid [11,12,26]. Sec-
ondly, the endpoint or evaluation indicators of amount
of study which investigated the predictive effects of
bone turnover markers. (i.e. NTx was SRE or progres-
sion of bone metastases) [11,16,26]. Although some stu-
dies found weekly low-dose zoledronic acid could
induce serum VEGF level reduction, and had potential
antitumor effects, they did not do the prognostic or
Zhao et al. BMC Cancer 2011, 11:403
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Page 8 of 10predictive factors analysis [7,17]. As a lot of reports used
urine NTx [11,12,23-26], we used serum NTx due to the
precision of time points of sample collection because
several biochemical markers such as VEGF in our pre-
vious study was collected concomitantly [8]. By doing
this, we can make the study more manageable and
decrease the impact of other factors like time, tempera-
ture, and storage, etc [27].
There are several strengths in our trial. First, it is a
prospective and randomized trial to investigate the prog-
nostic and predictive clinical or biochemical factors in
patients with bone metastases as the bone turnover mar-
kers. NTx, especially, can be a predictive factor in can-
cer patients with bone metastases receiving conventional
schedule of bisphosphonates. Our study further investi-
gates the NTx predictive value in a new weekly schedule
of low dose zoledronic acid. Secondly, recruitment of
patients were strictly limited to breast cancer patients
with bone metastases [8], thus the predictive effect of
NTx may be helpful for the individualized therapy. High
levels of baseline serum NTx may favor the weekly low-
dose zoledronic acid; however, there are several draw-
backs and limitation in our trial. First, weekly low-dose
zoledronic acid was no longer given in the metronomic
arm one month after the first drug administration. Dur-
i n gt h ef i r s tm o n t h ,t h em e t r o n o m i ca r ms h o w e das i g -
nificant reduction of VEGF and NTx compared with the
conventional arm. This effect may need to be sustained,
with higher frequency of zoledronic acid administration,
over a longer time period. Second, this is a single center
phase II trial. If the prognostic and predictive factors are
analyzed from several randomized phase III, double
blind studies, the results will be more credible. Thirdly,
in our previous study, all patients received chemother-
apy or hormonal therapy for a minimum of 28 days
after the first infusion of zoledronic acid according to
our institutional guidelines. No significant differences
were observed between the 2 arms in the use of differ-
ent agents due to a small sample size. This may poten-
tially have impact on PFS. Finally, the overall survival
results may be more credible for the evaluation of prog-
nostic or predictive factors; the results will be further
reported.
Conclusions
We conclude that numbers of pretreated chemotherapy
regimens, ER status, and baseline NTx and serum VEGF
level after 3 months are prognostic factors in breast can-
cer patients with bone metastases receiving zoledronic
acid. We firstly demonstrated that baseline NTx level
had a predictive value on progression-free survival in
patients treated with weekly low-dose of zoledronic acid,
indicating that those with higher NTx level might bene-
fit more from this new dosage. Our study maybe helpful
for individualized therapy, however, further evaluation
of the clinical and biochemical parameters of the weekly
low-dose zoledronic acid regimen of randomized phase
III study is warranted.
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